1.Determination of 11 Kinds of Phenol and Aniline Dyes in Oxidative Hair Dyes by High Performance Liquid Chromatography-Tandem Mass Spectrometry
Chaoying SHAO ; Ting QIN ; Duozhi SUN ; Jun LIU ; Yuwan SHAO
Chinese Journal of Analytical Chemistry 2014;(5):781-782
A method of simultaneous determination of the eleven phenol and aniline dyes in oxidative hair dyes by ultrasonic-assisted extraction and high performance liquid chromatography-tandem mass spectrometry was developed. The orthogonal and single-factor experiments were designed to and optimize the ultrasonic-assisted extraction conditions, and the samples were extracted using 10 mL of 5% methanol under the conditions of ascorbic acid as an antioxidant for 10 min. The gradient elution program and the electrospray ionization mode change were together used for the optimization of the measurements, and the determinations were completed by using the multi-reaction monitoring scan. The detection limits were 1. 15-9. 43 μg/g, the recoveries of spiked samples were 88. 0%-118. 1%. The method can be used to determine trace prohibited and restricted dyes in hair dyes.
2.Albumin-bound paclitaxel for treatment of patients with refractory metastatic breast cancer
Xu LIANG ; Huiping LI ; Lijun DI ; Hanfang JIANG ; Guohong SONG ; Ying YAN ; Chaoying WANG ; Bin SHAO ; Xiaolin LIN
China Oncology 2014;(11):836-845
Background and purpose:Nab-paclitaxel (Abraxane) is an albumin-bound form of paclitaxel that utilizes the natural properties of albumin to improve paclitaxel delivery to the tumor. It has recently been approved for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within short time after adjuvant chemotherapy. The purpose of this study was to evaluate the efifcacy and safety of albumin-bound paclitaxel in patients with aggressive and refractory metastatic breast cancer (MBC).Methods:A total of 58 patients with MBC were enrolled into this study from Jul. 2009 to Jan. 2014. All patients received albumin-bound paclitaxel-based chemotherapy. The adverse reactions were evaluated every cycle, and the short-term response was evaluated every two cycles. The patients were followed-up, and the survival was analyzed.Results:58 patients with refractory MBC were evaluable for response, 67.2% of patients received multiple line (≥3 lines) chemotherapy, 32.8% of patients with first and second line of chemotherapy were involved metastasis within one year after adjuvant chemotherapy, 84.5% of patients with visceral metastasis and 93.1% with prior taxane treatment. The objective response rate (ORR) was 13.8%, and disease control rate (DCR) was 60.3%, the median progression free survival (PFS) was 4.0 months, and the overall survival (OS) was 10.1 months. For 23 patients with triple negative breast cancer, ORR was 13.0% and DCR was 56.5%, the median PFS was 4.1 months, and OS was 6.6 months. The main toxicity was myelosuppression (grades 3 and 4 neutropenia, anemia and thombocytopenia were seen in 34.5%, 12.1% and 6.9% of patients, respectively), gastrointestinal reactions, sensory neuropathy, myodynia/arthragia, fatigue, alopecia and so on.Conclusion:The albumin-bound paclitaxel-based chemotherapy can be used in aggressive and refractory MBC. It also showed antitumor activity in taxanes-resistance patients and triple negative patients with good safety and tolerance.
3.Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer
Bin SHAO ; Huiping LI ; Lijun DI ; Guohong SONG ; Hanfang JIANG ; Xu LIANG ; Chaoying WANG ; Ying YAN ; Xiaolin LIN ; Lina WANG ; Fengling WAN ; Yanhua YUAN ; Miaoning YOU
Journal of Peking University(Health Sciences) 2016;48(2):304-309
Objective:To detect the proportion of lymphocyte subsets in peripheral blood of the ad-vanced breast cancer patients before and after chemotherapy with docetaxel and thiotepa,as well as the association between the proportion of peripheral blood lymphocyte subsets with the response rate and prog-nosis.Methods:The proportions of lymphocyte subsets (CD3 +T cell,CD3 +/CD4 +T cell,CD3 +/CD8 +T cell,CD3 -/CD16 +56 +NK cell,CD3 +/CD16 +56 +T cell,CD19 +B cell,CD4 +/CD25 +T cell,CD8 +/CD28 -T cell,CD8 +/CD28 +T cell)in the peripheral blood of 86 patients were analyzed with flowcytometry before and after chemotherapy.The result was analyzed in combination with clinico-pathological data.Results:The proportion of regulatory T cells (Treg)after chemotherapy in the disease control patients decreased significantly compared with that of the progressive patients (P=0.034).The difference of the proportions of Treg before and after chemotherapy affected significantly the overall survi-val (OS).The OS of the patients with decreased proportion of Treg was significantly longer than that of the patients with increased proportion of Treg,which was 23.5 and 9.4 months respectively (P<0.05). Conclusion:The patients with decreased proportion of Treg after chemotherapy had higher response rate and better survival benefit.